PMID- 32196006
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 24
IP  - 2
DP  - 2020 Apr 1
TI  - B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and 
      Management.
PG  - 199-204
LID - 10.1188/20.CJON.199-204 [doi]
AB  - Hematologic B-cell malignancies, which have varying behavior patterns, disease 
      processes, and treatment responses, include non-Hodgkin lymphoma, leukemias, and 
      myeloma. Although monoclonal antibodies and other agents have led to dramatic 
      advances in the treatment of B-cell malignancies, the development of small 
      molecules have enhanced the ability to treat and manage these malignancies and 
      their adverse events (AEs). Oncology nurses need to be educated on the unique 
      side effects for each class of these agents so that they can administer 
      interventions to prevent and manage AEs in patients.
FAU - Rogers, Barbara B
AU  - Rogers BB
AD  - Fox Chase Cancer Center.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
MH  - Antibodies, Monoclonal/*adverse effects/therapeutic use
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - B-Lymphocytes/pathology
MH  - Hematologic Neoplasms/*drug therapy
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell
MH  - Lymphoma, Non-Hodgkin
MH  - Multiple Myeloma/drug therapy
MH  - Oncology Nursing/*education
OTO - NOTNLM
OT  - B-cell malignancies
OT  - adverse events
OT  - hematologic malignancies
OT  - small molecule agents
EDAT- 2020/03/21 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/03/21 06:00
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
AID - 10.1188/20.CJON.199-204 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2020 Apr 1;24(2):199-204. doi: 10.1188/20.CJON.199-204.